Warburg Pincus and ArchiMed Invest in Polyplus-transfection
April 29, 2020
Warburg Pincus has made a major growth investment in Polyplus-transfection SA alongside existing majority shareholder ArchiMed, with both firms becoming equal shareholders while Polyplus management remains significant minority owners. The capital will be used to expand production capacity, accelerate product innovation, increase international expansion, and hire across technical, regulatory, and commercial functions to serve the gene and cell therapy market.
- Buyers
- Warburg Pincus, ArchiMed (ARCHIMED)
- Targets
- Polyplus-transfection SA
- Industry
- Biotechnology
- Location
- Grand Est, France
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Sartorius Stedim Biotech Acquires Polyplus
April 13, 2023
Biotechnology
Sartorius Stedim Biotech agreed to acquire Strasbourg-based Polyplus (Polyplus‑transfection S.A.) for €2.4 billion, pending customary regulatory approvals. The transaction buys the business from private equity backers including ARCHIMED and Warburg Pincus and strengthens Sartorius’s cell & gene therapy reagent and upstream bioprocessing portfolio.
-
ARCHIMED Invests in PlasmidFactory
October 7, 2022
Biotechnology
Transatlantic healthcare private equity firm ARCHIMED (via its MED Platform II fund) has invested in PlasmidFactory, a Bielefeld, Germany-based contract manufacturer of plasmid and minicircle DNA used in gene and cell therapies. The founder and management will remain in place with a roll-over of a portion of proceeds; proceeds will fund rapid expansion including construction of a larger GMP-compliant production facility to meet growing demand.
-
ARCHIMED Acquires Majority Stake in Xpress Biologics
October 5, 2021
Biotechnology
ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.
-
ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics
September 25, 2025
Biotechnology
ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.
-
ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)
November 3, 2021
Biotechnology
Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.
-
Warburg Pincus Acquires Pregis from Olympus Partners
June 5, 2019
Packaging
Warburg Pincus has agreed to acquire Pregis LLC, a leading manufacturer of protective packaging materials and automated systems, from Olympus Partners for an undisclosed amount. Pregis will continue to be led by CEO Kevin Baudhuin as Warburg Pincus partners with management to accelerate growth, expand capabilities in e-commerce enablement and automation, and build on recent European expansion.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.